Company Announcement No. 18/2025  Copenhagen, 8 December 2025 Scandinavian Tobacco Group A/S: Financial Calendar 2026 Scandinavian Tobacco Group A/S´ financial calendar for 2026: Full-year 2025 Annual Report     4 March 2026 Annual General Meeting            15 April 2026 Interim report Q1 2026               20 May 2026 Half-year report 2026                26 August 2026 Interim report Q3 2026               11 November 2026 For further information, please contact:Torben Sand, Director of IR & External Communication. +45 5084 7222 or torben.sand@st-group.com Eliza Dabbagh, IR and External Communication. +45 5080 7619 or eliza.michael@st-group.comAttachmentCompany Announcement no 18 2025

Frontline plc (the “Company”) advises that the 2025 Annual General Meeting of the Shareholders of the Company was held on 8 December 2025 at 09:00 a.m. at Metis Tower, 28th October Avenue and Iakovou Tombazi Street, 4th floor, 3107 Limassol, Cyprus. The audited consolidated financial statements for the Company for the year ended 31 December 2024 were presented to the Meeting. In addition, the following resolutions were passed:To re-elect John Fredriksen as a Director of the Company.To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect Cato Stonex as a Director of the Company. To re-elect Ørjan Svanevik as a Director of the Company. To re-elect Dr. Maria Papakokkinou as a Director of the Company To elect Richard C. Prince as a Director of the Company. To re-appoint...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,764,126 642.74 1,776,615,6311 December 2025 14,000 793.89 11,114,4642 December...

GMGI Appoints New CEONASDAQ: GMGI Announces New CEOGolden Matrix Group Announces the Retirement of CEO Brian Goodman, Appointment of William Scott as CEO and Launch of Next Phase of Strategic Execution LAS VEGAS, NV – December 8, 2025, Golden Matrix Group Inc. (NASDAQ: GMGI) (the “Company” and “Golden Matrix”), a global provider of online gaming platforms, content, and technology, today announced a planned leadership transition that aligns with the Company’s next phase of strategic execution and operational scale. Mr. Brian Goodman has agreed to step down as Chief Executive Officer and member of the Board of Directors of the Company effective December 12, 2025, unless an earlier date is agreed between Mr. Goodman and the Company. Mr. William Scott, Chairman of the Board and a globally recognized...

Diodon Drone, participation of Tonner Drones, accelerates its growth Paris, December 8th, 2025, 08:00, Tonner Drones (’the Company’) is pleased to announce that Diodon Drone, a participation of Tonner Drones, is confirming its growth path. Tonner Drones is also announcing that it is making progress in its investment- and treasury-strategy. Founded in 2017 in Toulouse, DIODON Drone Technology designs, produces and integrates a range of fully waterproof aerial drones dedicated to reconnaissance, surveillance and inspection missions in maritime, coastal and equatorial environments. Originally created to meet the operational needs of French special forces, DIODON now supports defense, security, rescue and offshore actors across Europe, West Africa and Southeast Asia. Diodon has informed Tonner Drones that it projects a revenue growth of over...

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapy In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistence IL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced the presentation of encouraging updated data of patients treated in the Phase 1 NATHALI-01 clinical trial with eti-cel, at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL. Eti-cel product candidate is the first allogeneic dual CAR-T targeting CD20 and CD22...

Sampo plc, stock exchange release, 8 December 2025 at 8:30 am EET Sampo plc’s share buybacks 5 December 2025 On 5 December 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  3,400 9.94 AQEU    102,542 9.95 CEUX  29,636 9.95 TQEX  133,434 9.95 XHELTOTAL 269,012 9.95  * rounded to two decimals                      On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025,...

OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment NANTES, France, December 8th, 2025 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced an amendment to its partnership agreement with AbbVie regarding ABBV-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage. Under the revised agreement, OSE Immunotherapeutics regains control of the early-stage development of the ABBV-230, while AbbVie maintains its rights to control future development and commercialization following successful completion of Phase 1. The revised approach reflects both parties’...

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy candidate, GLPG5101, during an oral presentation (#662) at the 67th American Society of Hematology (ASH) Annual Meeting. “The new and updated results from the Phase 2 ATALANTA-1 study demonstrate that GLPG5101 offers timely treatment with low rates of high-grade toxicities and durable responses for patients with relapsed or refractory MCL,” said Marie José Kersten, MD, ATALANTA-1 Principal Investigator and Professor...

BNP PARIBAS GROUP SELLS ITS STAKE IN AG INSURANCE AND FORMALISES LONG TERM PARTNERSHIP WITH AGEAS PRESS RELEASE Paris, 8 December 2025 On 7 December, the BNP Paribas and Ageas Groups signed a framework agreement. Centered on the Belgian bancassurance operations between AG Insurance and BNP Paribas Fortis, this partnership renews a long-standing exclusive collaboration and provides a sustainable framework for the activity’s accelerated development, particularly in the digital space. This partnership covers savings, protection and property & casualty insurance, and brings together BNP Paribas Fortis and AG Insurance’s expertise, as the leading insurer in Belgium, to serve their clients. AG Insurance and BNP Paribas Asset Management are also entering into a long-term investment partnership in certain asset classes, leveraging BNP Paribas...